



Jim Joyce
CEO, Inventor

FORWARD-LOOKING STATEMENTS

The following presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Sigyn Therapeutics, Inc. ("Sigyn"). All statements in this presentation, other than statements of historical fact, are forward-looking statements within the meaning of federal securities laws. In some cases, you can identify forward-looking statements by terms such as "may," "will," "expect," "plan," "anticipate," "strategy," "designed," "intend," "believe," "estimate," "target," or "potential" and other similar expressions. Forward-looking statements involve risks, uncertainties and assumptions that may cause Sigyn's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation, including risks and uncertainties inherent in Sigyn's business and other risks described in Sigyn's filings with the Securities and Exchange Commission (SEC). Sigyn's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading "Risk Factors" in Sigyn's periodic reports filed with the SEC, which are available on the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Sigyn undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Our Lead Product

Sigyn CardioDialysis™



**Cardiovascular Disease is the #1
Cause of Global Deaths**


**To Expand Kidney Dialysis Clinics into
Cardiovascular Treatment Centers**

**67% of Dialysis Patients
Die from Cardiovascular Disease**

Cardiovascular Disease (CVD)

- Reduction of **Major Adverse Cardiovascular Events (MACE)** is gold-standard clinical endpoint to evaluate benefit of CVD therapies
- Market for MACE reduction therapies estimated at **\$150-200 Billion**
- LDL-C Statins (Lipitor, Crestor, Zocor, etc.) reduce MACE by **25-35%**
- Lipoprotein Apheresis* (LA) devices that target circulating LDL-C and Lp(a) report MACE reductions of **55-95%**. An FDA-approved precedent


**Administration of LA is limited to specialized apheresis centers. 54 locations in the U.S.*



Sigyn CardioDialysis™ in Action

About CardioDialysis™

- ✓ Deployed on dialysis machines located in ~7,500+ U.S. Dialysis Clinics
- ✓ Overcomes limitation of single-target drugs
- ✓ Targets both LDL-C and Lp(a)
- ✓ Broad-spectrum clearance of inflammatory molecules that drive CVD progression



Sigyn CardioDialysis™ in Action

About CardioDialysis™

- ✓ Highly Efficient – Processes entire bloodstream ~15 times during a four-hour treatment
- ✓ Immense Capacity - Incorporates a formulation of adsorbent components with ~200,000 M² of surface area (50 acres) to remove CVD targets
- ✓ Conveniently administered during regularly scheduled ESRD-patient dialysis sessions

About End-Stage Renal Disease (ESRD) Dialysis Patients

- 550,000+ ESRD patients receive ~85 million dialysis treatments in the U.S. each year
- Average lifespan of 3-5 years once on dialysis
- Incidence of Cardiovascular Disease is 20x the general population
- Cardiovascular Disease accounts for 67% of deaths

Note: Infections account for 10.1% of ESRD deaths. Includes sepsis and pneumonia, which were lead treatment indications for Sigyn Therapy™ now being advanced as CardioDialysis™

Expanding Dialysis Clinics into CardioDialysis™ Treatment Centers

- We envision kidney dialysis clinics becoming *"Renal and CardioDialysis™ Treatment Centers"* in the future
- CardioDialysis™ introduces multibillion-dollar revenue opportunity to treat CVD in ESRD-patients
- Establishes pathway to treat CVD in non-ESRD-patients
- Reducing ESRD-patient hospitalizations recoups lost industry revenues
- Extending ESRD-patient lives markedly increases industry revenues

75% of U.S. Dialysis Patients are Treated by Fresenius & DaVita



38% Market Share



37% Market Share

Fresenius & DaVita Operate >5,250 U.S. Dialysis Clinics



>2,600 U.S. Dialysis Clinics



2,657 U.S. Dialysis Clinics

\$ Revenue Value for Extending ESRD Patient Lives



**~\$1 billion of increased revenue per Company
for each month of extended life**

\$ Revenue Value for Reducing ESRD Patient Hospitalizations



**~\$250 million in recouped revenues per Company
for each week of reduced hospitalization**

Sigyn CardioDialysis™ Clinical Plan

- Investigation Device Exemption (IDE) drafted for FDA submission
- Feasibility study protocol to enroll 12-15 ESRD subjects at three dialysis clinics
- Sigyn CardioDialysis™ to be administered in series with regular dialysis treatments
- Primary endpoint is safety / secondary endpoints – Changes in LDL-C, Lp(a), endotoxin, and inflammatory cytokine levels
- Successful study completion sets stage for in-clinic pivotal efficacy studies.

Sigyn CardioDialysis™

**Cardiovascular Disease is the #1
Cause of Global Deaths**

**To Expand Kidney Dialysis Clinics into
Cardiovascular Treatment Centers**



Jim Joyce
CEO, Inventor